Start with what life feels like now
Where does ketamine fit when depression persists?
We help people with depression or anxiety that disrupts daily life by considering mental and physical symptoms together so that they can work toward participating in relationships and routines again.
How we look at the whole picture
You have tried to explain how difficult ordinary days have become, and you may have already tried more than one approach.
Sleep, concentration, energy and physical symptoms may be adding to what you are carrying.
You do not need to know which treatment to ask for. Start with what has changed and what you want to be able to do again.
The 7 Domains of Recovery™
Your symptoms may belong in the same conversation.
Psychological health is one of seven domains, not an isolated part of you. We consider how mood, cognition, sleep, physical symptoms and circumstances affect each other.
Neuregen's proprietary 7 Domains of Recovery framework organizes that conversation around seven connected parts of your life and health. We consider all seven, then focus the evaluation on the questions your history raises.
Explore our clinical framework- 1Brain function & neural networks
What has changed in your memory, concentration, balance or sensory tolerance?
- 2Autonomic & nervous system regulation
What happens when you stand, move, rest or encounter stress?
- 3Immune function & neuroinflammation
What immune history, reactions or symptoms need a closer look?
- 4Brain energy & metabolic health
What affects your energy through the day and after activity?
- 5Structure, stability & body-to-brain signals
How do pain, posture, movement and stability affect what you can do?
- 6Psychological flexibility & behavioral recovery
How are mood, stress and patterns of coping affecting your day?
- 7Life, relationships & environment
What demands, relationships and support shape your recovery?
A plan starts with the things you want to do again.
We review your history, current symptoms, previous responses and priorities. You and the clinical team discuss the options, tradeoffs and how progress will be assessed.
01
Tell us what you want your life to look like
We start with what has changed, what you have tried, and the activities you most want to return to.
02
Answer the questions the history leaves open
We review prior reports and select relevant assessments. You should understand what each assessment is meant to clarify.
03
Agree on the priorities and the first steps
We discuss the findings, possible approaches, costs and practical constraints. The plan sets an order that fits your situation.
04
Check what changes and adjust together
We compare your response with the starting point, including daily function. If something is not helping, we discuss what needs to change.
Only then do we discuss which therapies, if any, belong in your plan. The choice depends on the findings, the evidence, your preferences and how you respond.
Talk through your situationKetamine Therapy · Indication
Ketamine for Depression & Anxiety
When a nervous system has been stuck in the same protective patterns for years, ketamine can open a window where real change becomes possible — and we make sure that window is used well.
Conceptual artwork for the care discussion. Individual findings and treatment options require clinical evaluation.
When standard depression treatment has not worked
Treatment-resistant depression is not simply depression that has not responded — it is often depression with an underlying neurobiology that standard antidepressants do not reach. Dysautonomia, neuroinflammation, and structural factors can all sustain a depressive state that monoamine-modulating drugs cannot resolve. At Neuregen, the workup for treatment-resistant depression includes the full domains assessment, not just a psychiatric evaluation.
Ketamine offers a mechanism that bypasses the monoamine system entirely: NMDA antagonism and downstream BDNF/mTOR-driven neuroplasticity. The result is a rapid antidepressant effect in many patients who have failed multiple prior treatments — and a neuroplastic window that, used well, can support more durable change.
Domains most involved:
Every plan starts from the same map: the 7 Domains of Recovery.
How it fits your plan
For depression or anxiety, we review previous approaches and your current needs. A recommendation depends on the assessment and an informed discussion, rather than a preset sequence of treatments.
Mood, sleep, concentration and physical symptoms can affect the same parts of your day. We consider them together before discussing a specific psychiatric approach, so psychotherapy or medication decisions fit the wider care plan.
We review your history, explain the findings, agree on next steps and check how you respond.
Potential Therapies
We use established medicine where it works, and emerging medicine where it makes sense.
These are options to discuss after evaluation, not a predetermined treatment plan. Each label refers to the condition or indication described beside that therapy; evidence can differ for another use. An evidence label does not mean FDA approval.
- Sub-anesthetic IV ketamineEvidence: Established
ESTABLISHED for treatment-resistant depression and major depressive disorder. Multiple randomized controlled trials, professional society recognition.
- Spravato (esketamine)Evidence: Established
FDA-approved intranasal esketamine for TRD and MDD with acute suicidal ideation. Insurance sometimes covers Spravato under its approved indications — discussed at the Strategy Consultation.
- KAP componentEvidence: Emerging
Structured psychotherapy integration for patients who benefit from therapeutic work within the neuroplastic window.
- PHQ-9, GAD-7 outcome tracking
Validated measures used to establish baseline and track response.
Where the evidence stands
Ketamine for treatment-resistant depression is supported by established clinical evidence — multiple randomized controlled trials, FDA approval of esketamine (Spravato) for TRD, and recognition by professional psychiatric societies. Anxiety outcomes are often measured alongside depression in these trials; the primary indication in the literature is depressive illness.
How we grade evidence
Pricing
| Service | Price |
|---|---|
| Ketamine therapy, single session | Confirmed in writing at your Strategy Consultation |
| Ketamine therapy, 6-session series | Confirmed in writing at your Strategy Consultation |
| Ketamine-assisted psychotherapy (KAP) sessionIncludes the psychotherapy component; priced separately from infusion-only sessions | Confirmed in writing at your Strategy Consultation |
| Ketamine maintenance sessionBooster sessions after a completed series, scheduled by response | Confirmed in writing at your Strategy Consultation |
Ketamine therapy is typically not covered by insurance. Spravato (esketamine) is sometimes covered when prescribed under its approved indications; we will tell you which applies to you before you commit.
Financing options are reviewed at your Strategy Consultation before any plan is finalized.
The training behind this care
Neuregen combines integrative psychiatric care with nervous-system rehabilitation. Our team can discuss psychological and physical concerns in the same clinical context, while explaining the qualifications and role of each treating clinician.
Dr. David George: Board certifications and training in functional neurology, integrative psychiatry, and mental health; certified brain injury specialist.
Training most relevant to this area
- Certified Clinical Trauma Professional (CCTP)
- PMHNP-BC
- Active Psychotherapist
- Certified Hypnotherapist
- CBT-I (Cognitive Behavioral Therapy for Insomnia) trained
These are the founder’s qualifications. We confirm the treating clinician and their role when discussing your plan.
See Dr. George’s full credentialsRelated pages
condition
Frequently asked questions
What is treatment-resistant depression?
Treatment-resistant depression (TRD) is generally defined as inadequate response to at least two antidepressant trials of adequate dose and duration. The underlying neurobiology of TRD often involves factors that standard antidepressants do not address — including autonomic dysregulation, neuroinflammation, and altered NMDA receptor function.
How quickly does ketamine work for depression?
Many patients with TRD notice an antidepressant effect within hours to days of the first infusion — a response timeline distinctly faster than conventional antidepressants. Duration of response varies; a structured course is typically more durable than a single infusion. Neuregen uses PHQ-9 tracking to measure response objectively.
Is Spravato (esketamine) the same as ketamine infusions?
Spravato is a nasal spray form of esketamine — the S-enantiomer of ketamine — FDA-approved for TRD and MDD with acute suicidal ideation. IV ketamine infusions use racemic ketamine and are off-label for depression, supported by a substantial evidence base. Neuregen will discuss which form is appropriate for your case at the Strategy Consultation.
Does ketamine help with anxiety as well as depression?
Anxiety outcomes are frequently measured alongside depression in ketamine trials, and many patients report improvement in anxiety symptoms. Anxiety is not a primary FDA indication for either ketamine or esketamine; clinical use for anxiety is based on the broader evidence base and clinical judgment.
Start with a Strategy Consultation
When distress or poor sleep keeps affecting relationships and everyday responsibilities, putting off a conversation leaves those concerns unresolved. You can ask about next steps without committing to medication or a procedure.
8090 N. 85th Way, Suite 100, Scottsdale, AZ 85258 · Mon–Thu, 9:00 AM – 5:30 PM